Successful Targeting of Alzheimer's Disease 2011

HUMAN GENETICS

What Can Recent Genetic Data Teach Us About Novel Therapeutics for Alzheimer’s Disease?
Rudolph Tanzi, Ph.D., Director, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease; Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School
A TOMM-40 Variable Length Polyt Repeat Polymorphism, Inherited through Evolution, Determines the Age of Onset Distribution of Late-Onset Alzheimer’s Disease
Allen D. Roses, M.D., Director, Deane Drug Discovery Institute, Duke University

TARGETS

Studies Probing the Mechanism of Action of Allosteric γ-Secretase Inhibitors and Modulators
Douglas S. Johnson, Ph.D., Senior Principal Scientist, Medicinal Chemistry, Pfizer, Inc.
Potential for the Treatment and Prevention of Alzheimer’s Disease with Liver X Receptor Agonist
Celina Zerbinatti, Ph.D., Team Lead, Cognitive Disorders, Department of Neurosymptomatic Disorders, Merck & Co., Inc.
Synaptic Zinc as a Pharmacological Target in Alzheimer’s Disease
Ashley I. Bush, M.D., Ph.D., Director, Oxidation Biology Laboratory, Mental Health Research Institute, Victoria, Australia; Professor of Pathology, University of Melbourne; Lecturer in Psychiatry, Harvard Medical School, Massachusetts General Hospital; Adjunct Professor of Neuroscience, Cornell University Medical Center, New York

ANIMAL MODELS

A Canine Model for Evaluating Gamma Secretase Modulators and Inhibitors
Herman Borghys, Ph.D., Neuroscience, Janssen Pharmaceutica, a division of Johnson & Johnson Pharmaceutical Research and Development

IMAGING & BIOMARKERS

The Impact of the ADNI on Drug Discovery & Development
William Potter, Ph.D., former Vice President, Translational Neuroscience, Merck Research Laboratories
Talk Title to be Announced
Leslie Shaw, Ph.D., Professor of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Expert